Senzime AB has announced two significant developments that strengthen its position in the neuromuscular monitoring market: securing one of its largest hospital system contracts to date and receiving a new U.S. patent for its TetraGraph technology.
Major Hospital System Deployment
The Swedish medical device company has secured a contract to supply 63 Next-generation TetraGraph monitors to one of the largest university hospital systems in the United States, with deployment planned at a medical center in Texas. The agreement includes collaborative Quality Improvement (QI) initiatives aimed at standardizing neuromuscular monitoring for more than 27,000 patients annually as an initial target.
"This marks another milestone for Senzime," said Philip Siberg, CEO of Senzime. "Not only have we secured one of our largest system-wide installations to date, but this project also serves as a benchmark for hospitals looking to implement QI initiatives in anesthesiology."
The collaboration will leverage Senzime's cloud-based TetraConnect platform to run anesthesiology-focused QI programs on large patient datasets. The company plans to utilize Artificial Intelligence analysis to unlock additional insights that may improve anesthesia care through a more personalized, data-driven approach to the administration and reversal of neuromuscular blocking agents (NMBAs).
Patent Protection Strengthens Technology Portfolio
Simultaneously, the United States Patent and Trademark Office has issued a new patent protecting key components of the TetraGraph system's proprietary algorithms. The patented innovation enhances the quality of electromyography (EMG)-based signals by filtering out external, periodic noise typically encountered in operating rooms.
This technological advancement results in enhanced and uninterrupted monitoring, accurate neuromuscular indications, personalized drug dosing capabilities, and optimized timing of extubation. The patent brings Senzime's total patent portfolio to 107 issued patents covering its technologies and products.
Clinical Significance and Market Position
The TetraGraph system is currently used in over 4,000 operating rooms worldwide and aligns with recently published U.S. and European guidelines recommending quantitative neuromuscular monitoring for all patients receiving NMBAs. The system enables anesthesiologists to accurately assess the depth of neuromuscular block, tailor dosing, and confirm when it is safe for patients to resume spontaneous breathing post-surgery.
These capabilities help reduce the risk of residual paralysis and enhance postoperative outcomes by allowing clinicians to accurately dose neuromuscular blocking agents and their antagonists, and determine when patients have safely recovered from anesthesia.
"Senzime continues to invest in and pioneer innovation in the field of neuromuscular monitoring, holding the most comprehensive IP portfolio in our industry niche," Siberg noted. "This new patent further strengthens our competitive advantage, enhances patient safety, and underscores our leadership in delivering personalized anesthesia solutions for the operating room."
Quality Improvement Integration
Quality Improvement programs have become essential in modern healthcare, leveraging real-world data to enhance efficiency and outcomes. Senzime's approach combines its TetraGraph system with the TetraConnect platform to offer novel abilities for running anesthesiology-focused QI programs on large patient datasets.
The company positions this as a turn-key solution enabling hospitals to transform how they monitor, manage, and protect patients during surgery. According to Siberg, "This is just the beginning of a new era in precise and personalized anesthesia."
